An intelligent search tool for clinical trials

Sign In
Back|NCT06674863Recruiting
Official Title

Addressing Health Literacy With a Tailored Survivorship Care Plan to Improve Access in Underserved African American Prostate Cancer Patients

Sponsor
Emory University
Enrollment
150
Timeline
Nov 2025 → Dec 2030
About This Study

This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.

Eligibility Criteria

Inclusion Criteria

  • 1Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
  • 2Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included

Exclusion Criteria

  • 1Dementia or cognitive impairment per provider clinical assessment
  • 2Unable to give informed consent in the judgement of the patient's oncology provider
  • 3Recurrent prostate cancer after primary treatment
  • 4Less than 18 years of age at the time of informed consent
  • 5Diagnosis of active second malignancy requiring treatment
  • 6Individuals who are not able to clearly understand English since the outcome measures require understanding of English

Locations

3 sites participating in this study

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia 30322

Recruiting

Viraj Master, MD, PhD, FACS

Grady Memorial Hospital

Atlanta, Georgia 30303

Recruiting

Viraj Master, MD, PhD, FACS

Atlanta VA Medical Center

Atlanta, Georgia 30329

Recruiting

Viraj Master, MD, PhD, FACS

Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →